[go: up one dir, main page]

MX2022007332A - Sistema terapeutico transmucoso que contiene agomelatina. - Google Patents

Sistema terapeutico transmucoso que contiene agomelatina.

Info

Publication number
MX2022007332A
MX2022007332A MX2022007332A MX2022007332A MX2022007332A MX 2022007332 A MX2022007332 A MX 2022007332A MX 2022007332 A MX2022007332 A MX 2022007332A MX 2022007332 A MX2022007332 A MX 2022007332A MX 2022007332 A MX2022007332 A MX 2022007332A
Authority
MX
Mexico
Prior art keywords
agomelatine
transmucosal
transmucosal therapeutic
system containing
therapeutic system
Prior art date
Application number
MX2022007332A
Other languages
English (en)
Inventor
Patrick Mohr
René Rietscher
René EIFLER
Olga Bourquain
Original Assignee
Lts Lohmann Therapie Systeme Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lts Lohmann Therapie Systeme Ag filed Critical Lts Lohmann Therapie Systeme Ag
Publication of MX2022007332A publication Critical patent/MX2022007332A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a sistemas terapéuticos transmucosales para la administración transmucosal de agomelatina que comprende una estructura de capa mucoadhesiva que comprende una cantidad terapéuticamente efectiva de agomelatina, tales sistemas terapéuticos transmucosales de agomelatina para uso en un método de tratamiento, un método de tratamiento que comprende aplicar tales sistemas terapéuticos transmucosales de agomelatina, y procesos de manufactura de tales sistemas terapéuticos transmucosales.
MX2022007332A 2019-12-20 2020-10-02 Sistema terapeutico transmucoso que contiene agomelatina. MX2022007332A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19218592 2019-12-20
PCT/EP2020/077736 WO2020260726A1 (en) 2019-12-20 2020-10-02 Transmucosal therapeutic system containing agomelatine

Publications (1)

Publication Number Publication Date
MX2022007332A true MX2022007332A (es) 2022-07-13

Family

ID=69411121

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007332A MX2022007332A (es) 2019-12-20 2020-10-02 Sistema terapeutico transmucoso que contiene agomelatina.

Country Status (11)

Country Link
US (1) US20220401389A1 (es)
EP (1) EP4076381B1 (es)
JP (1) JP2023506537A (es)
KR (1) KR20220118455A (es)
CN (2) CN115737607A (es)
AU (1) AU2020302262A1 (es)
BR (1) BR112022012139A2 (es)
CA (1) CA3162225A1 (es)
ES (1) ES3003263T3 (es)
MX (1) MX2022007332A (es)
WO (1) WO2020260726A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023170184A1 (en) * 2022-03-11 2023-09-14 Lts Lohmann Therapie-Systeme Ag Transmucosal therapeutic system containing a macrolide immunosuppressant
CN116832015A (zh) * 2023-08-21 2023-10-03 力品药业(厦门)股份有限公司 一种经口腔黏膜给药的阿戈美拉汀膜剂及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
AU769500B2 (en) * 1996-10-18 2004-01-29 Arius Two, Inc. Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
US8541021B2 (en) * 2001-05-01 2013-09-24 A.V. Topchiev Institute Of Petrochemical Synthesis Hydrogel compositions demonstrating phase separation on contact with aqueous media
FR2894475B1 (fr) * 2005-12-14 2008-05-16 Servier Lab Composition pharmaceutique orodispersible pour administra- -tion oromucosale ou sublinguale d'agomelatine
JP2014500258A (ja) * 2010-11-15 2014-01-09 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 制御放出粘膜付着システム
CN102579415B (zh) * 2011-01-14 2014-11-05 成都康弘药业集团股份有限公司 一种含有阿戈美拉汀的口腔粘膜或舌下给药的药物组合物
JP6591536B2 (ja) * 2014-06-10 2019-10-16 エーエフワイエックス・セラピューティクス・エー／エス 特定の投薬量の活性物質を皮膚又は粘膜に投与するための電気流体力学的に得られた繊維を含む組成物
WO2015189778A1 (en) * 2014-06-10 2015-12-17 Laboratorio Chimico Internazionale S.P.A. Agomelatine in solution adsorbates and compositions
US20160184246A1 (en) * 2014-12-30 2016-06-30 Noven Pharmaceuticals, Inc. Transdermal drug delivery systems for agomelatine
US20200297654A1 (en) * 2017-10-17 2020-09-24 Lubrizol Advanced Materials, Inc. Composition and device for delivery of active agents to skin surfaces

Also Published As

Publication number Publication date
CN113597303A (zh) 2021-11-02
AU2020302262A1 (en) 2022-06-02
KR20220118455A (ko) 2022-08-25
BR112022012139A2 (pt) 2022-10-04
EP4076381A1 (en) 2022-10-26
WO2020260726A1 (en) 2020-12-30
CN115737607A (zh) 2023-03-07
EP4076381C0 (en) 2024-12-04
ES3003263T3 (en) 2025-03-10
US20220401389A1 (en) 2022-12-22
CA3162225A1 (en) 2020-12-30
CN113597303B (zh) 2022-11-18
JP2023506537A (ja) 2023-02-16
EP4076381B1 (en) 2024-12-04

Similar Documents

Publication Publication Date Title
EP4378527A3 (en) Transmucosal therapeutic system containing agomelatine
MX382195B (es) Sistema terapeutico transdermico que contiene asenapina
ZA202202361B (en) Treatment of hidradenitis suppurativa using jak inhibitors
MX2020011653A (es) Métodos de tratamiento para el abuso de sustancias.
EP4417252A3 (en) Cannabis based therapeutic and method of use
MY199967A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
MX2022007332A (es) Sistema terapeutico transmucoso que contiene agomelatina.
MX2020014286A (es) Sistema terapeutico transdermico que contiene asenapina.
EP4434540A3 (en) Humanized anti-il-1r3 antibodies
EA202091640A1 (ru) Способы лечения опосредованного il-6 воспаления без иммунодепрессии
WO2018102687A3 (en) Combination therapy for treating cancer
PH12022550448A1 (en) Niclosamide delayed-release composition and antiviral use thereof
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
PH12021550965A1 (en) Combination therapy for treatment of hematological diseases
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
BR112022012111A2 (pt) Sistema terapêutico transdérmico contendo agomelatina
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
ZA202007615B (en) Dosing and effect of c5a antagonist with anca-associated vasculitis
IL284565A (en) A system for administering avalopertide transdermally and a method of use
BR112022009794A2 (pt) Método para tratar câncer no pulmão
SG11202105551YA (en) Process for producing pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
ZA201908087B (en) Treatment for migraine
TN2018000355A1 (en) Tetrahydropyran and thiopyran derivatives having multimodal activity against pain.
MX2021010402A (es) Tratamiento de la hidradenitis supurativa.
MY205171A (en) Methods of treatment of hypertriglyceridemia